Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: Prospective clinical and socioeconomic evaluation

Didier Blaise, Reza Tabrizi, Jean Marie Boher, Anne Gaëlle Le Corroller-Soriano, Jacques Olivier Bay, Nathalie Fegueux, Jean Michel Boiron, Sabine Fürst, Luca Castagna, Christian Chabannon, Agnes Boyer-Chammard, Noël Milpied, Hélène Labussière-Wallet, Catherine Faucher, Valerie Jeanne Bardou, Mohamad Mohty, Mauricette Michallet

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background: The optimal intensity of reduced-intensity conditioning (RIC) before allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains uncertain. Methods: In this centrally randomized phase 2 study, the authors compared 2 different strategies of RIC. In total, 139 patients (median age, 54 years; range, 21-65 years) with hematologic malignancies underwent allo-HSCT from a human leukocyte antigen-identical sibling after conditioning combining fludarabine with either busulfan and rabbit antithymocyte-globulin (BU-rATG) (n = 69) or total body irradiation (TBI) (n = 70). Postgraft immunosuppression consisted of cyclosporin A in all patients with the addition of mycophenolate-mophetil after TBI. Results: The median follow-up was 54 months (range, 26-88 months). One-year overall survival rate was identical in both groups. Four patients experienced graft-failure after TBI. The incidence of grade 2 through 4 acute graft-versus-host-disease was greater after BU-rATG than after TBI (47% vs 27%; P =.01), whereas no difference was observed with chronic graft-versus-host-disease. The BU-rATG group had a higher objective response rate (65% vs 46%; P =.05) and a lower relapse rate (27% vs 54%; P

Original languageEnglish
Pages (from-to)602-611
Number of pages10
JournalCancer
Volume119
Issue number3
DOIs
Publication statusPublished - Feb 1 2013

Fingerprint

Peripheral Blood Stem Cell Transplantation
Whole-Body Irradiation
HLA Antigens
Busulfan
Antilymphocyte Serum
Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Rabbits
Hematologic Neoplasms
Immunosuppression
Cyclosporine
Siblings
Survival Rate
Transplants
Recurrence
Conditioning (Psychology)
Incidence

Keywords

  • allogenic hematopoietic stem cell transplantation
  • conditioning
  • hematologic malignancies
  • reduced intensity
  • socioeconomic evaluation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation : Prospective clinical and socioeconomic evaluation. / Blaise, Didier; Tabrizi, Reza; Boher, Jean Marie; Le Corroller-Soriano, Anne Gaëlle; Bay, Jacques Olivier; Fegueux, Nathalie; Boiron, Jean Michel; Fürst, Sabine; Castagna, Luca; Chabannon, Christian; Boyer-Chammard, Agnes; Milpied, Noël; Labussière-Wallet, Hélène; Faucher, Catherine; Bardou, Valerie Jeanne; Mohty, Mohamad; Michallet, Mauricette.

In: Cancer, Vol. 119, No. 3, 01.02.2013, p. 602-611.

Research output: Contribution to journalArticle

Blaise, D, Tabrizi, R, Boher, JM, Le Corroller-Soriano, AG, Bay, JO, Fegueux, N, Boiron, JM, Fürst, S, Castagna, L, Chabannon, C, Boyer-Chammard, A, Milpied, N, Labussière-Wallet, H, Faucher, C, Bardou, VJ, Mohty, M & Michallet, M 2013, 'Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: Prospective clinical and socioeconomic evaluation', Cancer, vol. 119, no. 3, pp. 602-611. https://doi.org/10.1002/cncr.27786
Blaise, Didier ; Tabrizi, Reza ; Boher, Jean Marie ; Le Corroller-Soriano, Anne Gaëlle ; Bay, Jacques Olivier ; Fegueux, Nathalie ; Boiron, Jean Michel ; Fürst, Sabine ; Castagna, Luca ; Chabannon, Christian ; Boyer-Chammard, Agnes ; Milpied, Noël ; Labussière-Wallet, Hélène ; Faucher, Catherine ; Bardou, Valerie Jeanne ; Mohty, Mohamad ; Michallet, Mauricette. / Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation : Prospective clinical and socioeconomic evaluation. In: Cancer. 2013 ; Vol. 119, No. 3. pp. 602-611.
@article{ec43c25d33d94c3e8790b40d5ef10afa,
title = "Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: Prospective clinical and socioeconomic evaluation",
abstract = "Background: The optimal intensity of reduced-intensity conditioning (RIC) before allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains uncertain. Methods: In this centrally randomized phase 2 study, the authors compared 2 different strategies of RIC. In total, 139 patients (median age, 54 years; range, 21-65 years) with hematologic malignancies underwent allo-HSCT from a human leukocyte antigen-identical sibling after conditioning combining fludarabine with either busulfan and rabbit antithymocyte-globulin (BU-rATG) (n = 69) or total body irradiation (TBI) (n = 70). Postgraft immunosuppression consisted of cyclosporin A in all patients with the addition of mycophenolate-mophetil after TBI. Results: The median follow-up was 54 months (range, 26-88 months). One-year overall survival rate was identical in both groups. Four patients experienced graft-failure after TBI. The incidence of grade 2 through 4 acute graft-versus-host-disease was greater after BU-rATG than after TBI (47{\%} vs 27{\%}; P =.01), whereas no difference was observed with chronic graft-versus-host-disease. The BU-rATG group had a higher objective response rate (65{\%} vs 46{\%}; P =.05) and a lower relapse rate (27{\%} vs 54{\%}; P",
keywords = "allogenic hematopoietic stem cell transplantation, conditioning, hematologic malignancies, reduced intensity, socioeconomic evaluation",
author = "Didier Blaise and Reza Tabrizi and Boher, {Jean Marie} and {Le Corroller-Soriano}, {Anne Ga{\"e}lle} and Bay, {Jacques Olivier} and Nathalie Fegueux and Boiron, {Jean Michel} and Sabine F{\"u}rst and Luca Castagna and Christian Chabannon and Agnes Boyer-Chammard and No{\"e}l Milpied and H{\'e}l{\`e}ne Labussi{\`e}re-Wallet and Catherine Faucher and Bardou, {Valerie Jeanne} and Mohamad Mohty and Mauricette Michallet",
year = "2013",
month = "2",
day = "1",
doi = "10.1002/cncr.27786",
language = "English",
volume = "119",
pages = "602--611",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation

T2 - Prospective clinical and socioeconomic evaluation

AU - Blaise, Didier

AU - Tabrizi, Reza

AU - Boher, Jean Marie

AU - Le Corroller-Soriano, Anne Gaëlle

AU - Bay, Jacques Olivier

AU - Fegueux, Nathalie

AU - Boiron, Jean Michel

AU - Fürst, Sabine

AU - Castagna, Luca

AU - Chabannon, Christian

AU - Boyer-Chammard, Agnes

AU - Milpied, Noël

AU - Labussière-Wallet, Hélène

AU - Faucher, Catherine

AU - Bardou, Valerie Jeanne

AU - Mohty, Mohamad

AU - Michallet, Mauricette

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Background: The optimal intensity of reduced-intensity conditioning (RIC) before allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains uncertain. Methods: In this centrally randomized phase 2 study, the authors compared 2 different strategies of RIC. In total, 139 patients (median age, 54 years; range, 21-65 years) with hematologic malignancies underwent allo-HSCT from a human leukocyte antigen-identical sibling after conditioning combining fludarabine with either busulfan and rabbit antithymocyte-globulin (BU-rATG) (n = 69) or total body irradiation (TBI) (n = 70). Postgraft immunosuppression consisted of cyclosporin A in all patients with the addition of mycophenolate-mophetil after TBI. Results: The median follow-up was 54 months (range, 26-88 months). One-year overall survival rate was identical in both groups. Four patients experienced graft-failure after TBI. The incidence of grade 2 through 4 acute graft-versus-host-disease was greater after BU-rATG than after TBI (47% vs 27%; P =.01), whereas no difference was observed with chronic graft-versus-host-disease. The BU-rATG group had a higher objective response rate (65% vs 46%; P =.05) and a lower relapse rate (27% vs 54%; P

AB - Background: The optimal intensity of reduced-intensity conditioning (RIC) before allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains uncertain. Methods: In this centrally randomized phase 2 study, the authors compared 2 different strategies of RIC. In total, 139 patients (median age, 54 years; range, 21-65 years) with hematologic malignancies underwent allo-HSCT from a human leukocyte antigen-identical sibling after conditioning combining fludarabine with either busulfan and rabbit antithymocyte-globulin (BU-rATG) (n = 69) or total body irradiation (TBI) (n = 70). Postgraft immunosuppression consisted of cyclosporin A in all patients with the addition of mycophenolate-mophetil after TBI. Results: The median follow-up was 54 months (range, 26-88 months). One-year overall survival rate was identical in both groups. Four patients experienced graft-failure after TBI. The incidence of grade 2 through 4 acute graft-versus-host-disease was greater after BU-rATG than after TBI (47% vs 27%; P =.01), whereas no difference was observed with chronic graft-versus-host-disease. The BU-rATG group had a higher objective response rate (65% vs 46%; P =.05) and a lower relapse rate (27% vs 54%; P

KW - allogenic hematopoietic stem cell transplantation

KW - conditioning

KW - hematologic malignancies

KW - reduced intensity

KW - socioeconomic evaluation

UR - http://www.scopus.com/inward/record.url?scp=84872926398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872926398&partnerID=8YFLogxK

U2 - 10.1002/cncr.27786

DO - 10.1002/cncr.27786

M3 - Article

C2 - 22893313

AN - SCOPUS:84872926398

VL - 119

SP - 602

EP - 611

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -